Atrium Post Acute Care Of Matawan | |
38 Freneau Avenue, Matawan, New Jersey 07747 | |
(732) 765-5600 | |
Name | Atrium Post Acute Care Of Matawan |
---|---|
Location | 38 Freneau Avenue, Matawan, New Jersey |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 130 |
Occupancy Rate | 62.08% |
Medicare ID (CCN) | 315463 |
Legal Business Name | 38 40 Freneau Avenue Operating Company Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1285292185 |
Organization Name | MATAWAN SNF AMOP, LLC |
Doing Business As | SPRING HILLS POST ACUTE MATAWAN (VENT) |
Address | 38 Freneau Ave, Matawan, NJ 07747 |
Phone Number | 732-765-5600 |
News Archive
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
The American Medical Group Association today announced a partnership venture with Avatar Solutions to provide enhanced services for its Patient Satisfaction Benchmarking (PSAT) Program.
Drinking red grape juice or wine - in moderation - could improve the health of overweight people by helping them burn fat better, according to a new study coauthored by an Oregon State University researcher.
› Verified 8 days ago
NPI Number | 1548971765 |
Organization Name | MATAWAN SNF OPERATIONS LLC |
Address | 38 Freneau Ave, Matawan, NJ 07747 |
Phone Number | 732-765-5600 |
News Archive
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
The American Medical Group Association today announced a partnership venture with Avatar Solutions to provide enhanced services for its Patient Satisfaction Benchmarking (PSAT) Program.
Drinking red grape juice or wine - in moderation - could improve the health of overweight people by helping them burn fat better, according to a new study coauthored by an Oregon State University researcher.
› Verified 8 days ago
NPI Number | 1619439312 |
Organization Name | MATAWAN SNF AMOP, LLC |
Doing Business As | SPRING HILLS POST ACUTE MATAWAN (SNF) |
Address | 38 Freneau Ave, Matawan, NJ 07747 |
Phone Number | 732-765-5600 |
News Archive
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
The American Medical Group Association today announced a partnership venture with Avatar Solutions to provide enhanced services for its Patient Satisfaction Benchmarking (PSAT) Program.
Drinking red grape juice or wine - in moderation - could improve the health of overweight people by helping them burn fat better, according to a new study coauthored by an Oregon State University researcher.
› Verified 8 days ago
NPI Number | 1932450863 |
Organization Name | ATRIUM AT MATAWAN |
Doing Business As | ATRIUM POST ACUTE CARE OF MATAWAN |
Address | 38 Freneau Ave, Matawan, NJ 07747 |
Phone Number | 732-765-5600 |
News Archive
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
The American Medical Group Association today announced a partnership venture with Avatar Solutions to provide enhanced services for its Patient Satisfaction Benchmarking (PSAT) Program.
Drinking red grape juice or wine - in moderation - could improve the health of overweight people by helping them burn fat better, according to a new study coauthored by an Oregon State University researcher.
› Verified 8 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
The American Medical Group Association today announced a partnership venture with Avatar Solutions to provide enhanced services for its Patient Satisfaction Benchmarking (PSAT) Program.
Drinking red grape juice or wine - in moderation - could improve the health of overweight people by helping them burn fat better, according to a new study coauthored by an Oregon State University researcher.
› Verified 8 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 10.08 | 14.46 |
Percentage of long-stay residents who lose too much weight | 11.31 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 59.46 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.3 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.32 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.06 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 0.63 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.8 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 5.99 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 82.87 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0.65 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 11.2 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.13 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 16.02 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.48 | 95.98 |
Percentage of short-stay residents who made improvements in function | 77.94 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 85.05 | 82.93 |
News Archive
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).
Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).
The American Medical Group Association today announced a partnership venture with Avatar Solutions to provide enhanced services for its Patient Satisfaction Benchmarking (PSAT) Program.
Drinking red grape juice or wine - in moderation - could improve the health of overweight people by helping them burn fat better, according to a new study coauthored by an Oregon State University researcher.
› Verified 8 days ago
Atrium Post Acute Care Of Matawan Location: 38 Freneau Avenue, Matawan, New Jersey 07747 Phone: (732) 765-5600 |